GleamWall
中文EN

SION Sionna Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2036042 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-55.0%
TTM EPS YoY47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-39.0%
ROA-36.4%
ROIC (approx.)-44.5%
Asset turnover—

Leverage & solvency

Liabilities / assets8.6%
Debt / equity0.00x
Current ratio13.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$22.02M$21.86M$18.96M$15.17M$16.04M$15.38M$13.67M$14.25M
SG&A expense$12.79M$10.61M$10.64M$8.44M$7.76M$6.52M$5.99M$3.88M
Operating income-$34.82M-$32.47M-$29.60M-$23.61M-$23.80M-$21.91M-$19.66M-$18.13M
Net income-$32.42M-$29.89M-$26.78M-$20.44M-$20.28M-$18.07M-$16.48M-$15.85M
EBITDA-$34.62M-$32.27M-$29.45M-$23.46M-$23.70M-$21.81M-$19.50M-$17.97M
EPS (basic)-0.72-0.66-0.60—-0.46-0.41-0.62—
EPS (diluted)-0.72-0.66-0.60—-0.46-0.41-0.62—
Weighted avg. shares (diluted)45.21M45.15M44.92M—44.26M44.12M26.60M—
Balance sheet
Cash & equivalents$83.88M$63.32M$63.32M$58.45M$50.83M$40.98M$82.69M$38.75M
Current assets$228.53M$216.13M$220.96M$241.42M$252.33M$266.75M$273.68M$150.99M
PP&E, net$1.76M$1.92M$2.07M$2.23M$2.14M$2.25M$2.39M$2.47M
Total assets$263.26M$283.25M$305.04M$325.95M$339.27M$352.05M$369.67M$185.75M
Current liabilities$16.42M$10.78M$9.78M$11.71M$9.85M$7.55M$9.53M$10.42M
Total liabilities$22.74M$17.47M$16.83M$19.12M$17.60M$15.62M$17.91M$19.10M
Shareholders' equity$240.52M$265.77M$288.21M$306.83M$321.67M$336.43M$351.77M-$163.71M
Shares outstanding45.21M45.16M45.08M44.72M44.46M44.13M44.09M4.72M
Cash flow statement
Operating cash flow-$18.72M-$22.22M-$21.84M-$16.63M-$15.23M-$18.15M-$16.29M-$11.78M
Capital expenditure$0$0$0$204,000$87,000$0$86,000$27,000
Free cash flow-$18.72M-$22.22M-$21.84M-$16.83M-$15.32M-$18.15M-$16.37M-$11.81M
Investing cash flow$38.95M$21.47M$24.82M$22.59M$23.10M-$23.25M-$141.19M$15.23M
Financing cash flow$333,000$749,000$1.89M$1.66M$1.97M-$312,000$202.39M-$1.41M
Depreciation & amortization$200,000$200,000$154,000$152,000$100,000$100,000$159,000$167,000
Stock-based compensation$7.08M$6.84M$6.55M$3.83M$3.31M$2.84M$2.09M$1.06M

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.